Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study).

S L Galetta1

  • 1Department of Neurology, University of Pennsylvania, Philadelphia 19104, USA. galetta@mail.med.upenn.edu

Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|January 5, 2002
PubMed
Summary

Interferon beta-1a (Avonex) significantly reduced the risk of developing multiple sclerosis (MS) by 44% in patients experiencing a first demyelinating event. Avonex also decreased new MRI lesions, showing its efficacy in early MS treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Covid-19 vaccination and possible link to Herpes zoster.

American journal of ophthalmology case reports·2022
Same author

Selective intra-arterial thrombolysis in acute stroke: Implications for emergency management.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

The King-Devick test as a concussion screening tool administered by sports parents.

The Journal of sports medicine and physical fitness·2014
Same author

Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study.

Neurology·2011
Same author

The King-Devick test as a determinant of head trauma and concussion in boxers and MMA fighters.

Neurology·2011
Same author

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Neurology·2009

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Early intervention in patients with a first demyelinating event may alter disease course.
  • Magnetic Resonance Imaging (MRI) abnormalities predict future MS development.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta-1a (Avonex) in patients with a first acute demyelinating event and MRI-predicted high risk of MS.
  • To assess the impact of Avonex on the development of clinically definite MS and MRI-detected lesions.

Main Methods:

  • The Controlled High Risk Avonex Multiple Sclerosis Study (CHAMPS) randomized 383 patients to Avonex or placebo.
  • Both groups received initial treatment with methylprednisolone and prednisone.

Related Experiment Videos

  • Patients were followed for 3 years to monitor clinical and MRI outcomes.

    • Main Results:

    • Avonex treatment reduced the 3-year cumulative probability of developing clinically definite MS by 44% (RR 0.56, P = 0.002).
    • Avonex significantly reduced new T2 lesions, gadolinium-enhanced lesions, and T2 lesion volume at 18 months.
    • 82% of placebo patients developed new subclinical MRI abnormalities by 18 months.

    Conclusions:

    • Interferon beta-1a (Avonex) is effective in reducing the likelihood of developing clinically definite MS after a first CNS demyelinating event.
    • Avonex therapy demonstrates significant benefits in mitigating MRI lesion activity in early MS.
    • Treatment with Avonex supports the efficacy in preventing future neurological events and worsening brain MRI in high-risk patients.